Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer

Bibliography

• GALLI SJ: New concepts about the mast cell. N Engl. J. Med. (1993) 328(4):257–265.
   PubMed Web of Science ®Google Scholar
• KINET JP: The high-affinity IgE receptor (Fc_RI) from physiology to pathology. Ann. Rev Immunol (1999) 17:931–972.
   PubMed Web of Science ®Google Scholar
• MIESCHER SM, VOGEL M: Molecular aspects of allergy. MM. Aspects Med. (2002) 236(6):413–462.
   Web of Science ®Google Scholar
• VON BUBNOFF D, NOVAK N, KRAFT S, BIEBER T: The central role of FccRI in allergy. Clin. Exp. Dermatol (2003) 28(2):184–187.
   PubMed Web of Science ®Google Scholar
• SANTAMARIA P: Effector lymphocytes in autoimmunity. Curr. Opin. Immunol (2001) 13(6):663–669.
   PubMed Web of Science ®Google Scholar
• BENDELAC A, BONNEVILLE M, KEARNEY JF: Autoreactivity by design: innate B and T lymphocytes. Nat. Rev Immunol (2001) 1(3):177–186.
   PubMed Web of Science ®Google Scholar
• HEYMAN B: Regulation of antibody responses via antibodies, complement, and Fc receptors. Ann. Rev Immunol (2000) 18:709–737.
   PubMed Web of Science ®Google Scholar
• RAVETCH JV, BOLLAND S: IgG Fc receptors. Ann. Rev Immunol (2001) 19:275–290.
   PubMed Web of Science ®Google Scholar
• TAKAI T: Roles of Fc receptors in autoimmunity. Nat. Rev Immunol (2002) 2(8):580–592.
   PubMed Web of Science ®Google Scholar
• ••General overview of FcRs specialised in autoimmune diseases.
   Google Scholar
• HOGARTH PM: Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol (2002) 14(6):798–802.
   PubMed Web of Science ®Google Scholar
• SHIBUYA A, SAKAMOTA N, SHIMIZU Y et al.: Fc a/µ receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol (2000) 1(5):441–446.
   PubMed Web of Science ®Google Scholar
• •Describes a recently discovered FcR that binds to both IgA and IgM.
   Google Scholar
• ROOPENIAN DC, CHRISTIANSON GJ, SPROULE TJ et al.: The MHC Class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Clin. Invest. (2004) 113(9):1328–1333.
   PubMed Web of Science ®Google Scholar
• RADSTAKE TR, PETIT E, PIERLOT C, VAN DE PUTTE LB, CORMELIS F, BARRERA P: Role of Fey receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis. Rheumatol (2003) 30(5):926–933.
   Web of Science ®Google Scholar
• KYOGOKU C, T SUCHIYA N, MATSUTA K, TOKUNAGA K: Studies on the association of Fey receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A. Genes. Immun. (2002) 3(8):488–493.
   PubMed Web of Science ®Google Scholar
• TSUCHIYA N, OHASHI J, TOKUNAGA K: Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev (2002) 190:169–181.
   PubMed Web of Science ®Google Scholar
• KARASSA FB, TRIKALINOS TA, IOANNIDIS JP: FcyRIIA-SLE Meta-Analysis Investigators: role of the Fey receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis. Rheum. (2002) 46(6):1563–1571.
   PubMed Web of Science ®Google Scholar
• EDBERG JC, WAINSTEIN E, WU J et al.: Analysis of FcyRII gene polymorphisms in Wegener's granulomatosis. Exp. Clin. Immunogenet. (1997) 14(3):183–195.
   PubMedGoogle Scholar
• NIETO A, CALIZ R, PASCUAL M, MATARAN L, GARCIA S, MARTIN J: Involvement of Fey receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum. (2000) 43(4):735–739.
   PubMed Web of Science ®Google Scholar
• MORGAN AW, KEYTE VH, BABBAGE SJ et al.: FcyRIIIA-158V and rheumatoid arthritis: a confirmation study. Rheumatology (2003) 42(4):528–533.
   PubMed Web of Science ®Google Scholar
• HATTA Y, TSUCHIYA N, OHASHI J et al: Association of Fey receptor IIIB, but not of Fey receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese. Genes Immun. (1999) 1(1):53–60.
   PubMed Web of Science ®Google Scholar
• SONDERMANN P, HUBER R, OOSTUIZEN V, JACOB U: The 3.2-A crystal structure of the human IgG1 Fc fragment-FcyRIII complex. Nature (2000) 406(6793):267–273.
   Google Scholar
• GARMAN SC, WURZBURG BA, TARCHEVSKAYA SS, KINET JP, JARDETZKY TS: Structure of the Fc fragment of human IgE bound to its high-affinity receptor FccRI alpha. Nature (2000) 406(6793):259–266.
   PubMed Web of Science ®Google Scholar
• HERR AB, BALLISTER ER, BJORKMAN PJ: Insights into IgA-mediated immune responses from the crystal structures of human FcaRI and its complex with IgAl-Fc. Nature (2003) 423(6940):614–620.
   PubMed Web of Science ®Google Scholar
• RADAEV S, MOTYKA S, FRIDMAN WH, SAUTES-FRIDMAN C, SUN PD: The structure of a human Type III Fey receptor in complex with Fc. J. Biol. Chem. (2001) 276(19):16469–16477.
   PubMed Web of Science ®Google Scholar
• ••[21-24] demonstrated the bindingInteraction between FcRs and Ig-Fc fragments at an atomic level.
   Google Scholar
• WOOF JM, BURTON DR: Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol (2004) 4(2):89–99.
   PubMed Web of Science ®Google Scholar
• ••General overview of the crystalstructure of FcR.
   Google Scholar
• MAXWELL KF, POWELL MS, HULETT MD et al.: Crystal structure of the human leukocyte Fc receptor, FcyRIIa. Nat. Struct. Biol. (1999) 6(5):437–442.
   PubMedGoogle Scholar
• SONDERMANN P, HUBER R, JACOB U: Crystal structure of the soluble form of the human Fey-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO (1999) 18(5):1095–1103.
   Google Scholar
• GARMAN SC, KINET JP, JARDETZKY TS: Crystal structure of the human high-affinity IgE receptor. Cell (1998) 95(7):951–961.
   PubMed Web of Science ®Google Scholar
• DINGY, XU G, YANG M et al: Crystal structure of the ectodomain of human FcaRI. I. Biol. Chem. (2003) 278(30):27966–27970.
   Web of Science ®Google Scholar
• WILLCOX BE, THOMAS LM, BJORKMAN PJ: Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat. Immunol (2003) 4(9):913–919.
   PubMed Web of Science ®Google Scholar
• CHAPMAN TL, HEIKEMA AP, WEST AP, BJOEKMAN PJ: Crystal structure and ligand binding properties of the D1D 2 region of the inhibitory receptor LIR-1 (ILT2) Immunity (2000) 13(5):727–736.
   Google Scholar
• GHAZIZADEH S, BOLEN JB, FLEIT HB: Physical and functional association of Src-related protein tyrosine kinases with FcyRII in monocytic THP-1 cells. J. Biol. Chem. (1994) 269(12):8878–8884.
   PubMed Web of Science ®Google Scholar
• WANG AV, SCHOLL PR, GEHA RS: Physical and functional association of the high affinity immunoglobulin G receptor (FcyRI) with the kinases Hck and Lyn. J. Exp. Med. (1994) 180(3):1165–1170.
   PubMed Web of Science ®Google Scholar
• BOLLAND S, PEARSE RN, KUROSAKI T, RAVETCH JV: SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity (1998) 8(4):509–516.
   PubMed Web of Science ®Google Scholar
• FLUCKIGER AC, LIZ, KATO RM et al: Btk/Tec kinases regulate sustained increases in intracellular Ca2' following B-cell receptor activation. EMBO J. (1998) 17(7):1973–1985.
   PubMed Web of Science ®Google Scholar
• SCHARENBERG AM, EL-HILLAL 0, FRUMAN DA et al.: Phosphatidylinosito1-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. (1998) 17(7):1961–1672.
   Google Scholar
• TAMIR I, STOLPA JC, HELGASON CD et al: The RasGAP-binding protein p62dok is a mediator of inhibitory FcyRIIB signals in B cells. Immunity(2000) 12(3):347–358.
   PubMed Web of Science ®Google Scholar
• TAKAI T, ONO M, HIKIDA M, OHOMORI H, RAVETCH JV: Augmented humoral and anaphylactic responses in FcyRII-deficient mice. Nature (1996) 379(6563):346–349.
   PubMed Web of Science ®Google Scholar
• ••First report of in vivo function of FcyRIIB
   Google Scholar
• PEARSE RN, KAWABE T, BOLLAND S, GUINAMARD R, KUROSKI T, RAVETCH JV: SHIP recruitment attenuates FcyRIIB-induced B cell apoptosis. Immunity (1999) 10(6):753–760.
   PubMed Web of Science ®Google Scholar
• JIANG Y, HIROSE S, ABE M et al: Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics (2000) 51(6):429–435.
   PubMed Web of Science ®Google Scholar
• XIU Y, NAKAMURA K, ABE M et al: Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. Immunol. (2002) 169(8):4340–4346.
   Web of Science ®Google Scholar
• KAWAKAMI T, GALLI SJ: Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev Immunol. (2002) 2(10):773–786.
   PubMed Web of Science ®Google Scholar
• TRACZYK C, OKAYAMA Y, METCALFE DD, GLIFILLAN AM: Fey receptors on mast cells: activating and inhibitory regulation of mediator release. Int. Arch. Allergy Immunol. (2004) 133(3):305–315.
   PubMed Web of Science ®Google Scholar
• PRIBLUDA VS, PRIBLUDA C, METZGER H: Transphosphorylation as the mechanism by which the high-affinity receptor for IgE is phosphorylated upon aggregation. Proc. Natl. Acad. Sci. USA (1994) 91(23):11246–11250.
   PubMed Web of Science ®Google Scholar
• EL-HILLAL 0, KUROSAKI T, YAMAMURA H, KINET JP, SCHARENBERG AM: Syk kinase activation by a src kinase-initiated activation loop phosphorylation chain reaction. Proc. Natl. Acad. Li. USA (1997) 94(5):1919–1924.
   PubMed Web of Science ®Google Scholar
• SAITOH S, ARUDCHANDRAN R, MANETZ TS et al: LAT is essential for FccRI-mediated mast cell activation. Immunity (2000) 12(5):525–535.
   PubMed Web of Science ®Google Scholar
• BARKER SA, LUJAN D, WILSON BS: Multiple roles for PI 3-kinase in the regulation of PLC-y activity and Ca2' mobilization in antigen-stimulated mast cells. J. Leukoc. Biol. (1999) 65(3):321–329.
   PubMed Web of Science ®Google Scholar
• GU H, PRATT JC, BURAKOFF SJ, NEEL BG: Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mot Cell. (1998) 2(6):729–740
   PubMed Web of Science ®Google Scholar
• PARRAVICINI V, GADINA M, KOVAROVA M et al: Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. (2002) 3(8):741–748.
   PubMed Web of Science ®Google Scholar
• FUKAO T, TERAUCHI Y, KADOWAKI T, KOYASU S: Role of phosphoinositide 3-kinase signaling in mast cells: new insights from knockout mouse studies. J. Mot Med. (2003) 81(9):524–535.
   PubMed Web of Science ®Google Scholar
• WILSON BS, PFEIFFER JR, OLIVER JM: FcnRI signaling observed from the inside of the mastcell membrane. Mot Immunol. (2002) 38(16-18):1259–1268.
   Web of Science ®Google Scholar
• GARCIA-GARCIA E, ROSALES C: Signal transduction during Fc receptor-mediated phagocytosis. Leukoc. Biol. (2002) 72(6):1092–1108.
   PubMed Web of Science ®Google Scholar
• COX D, GREENBERG S: Phagocytic signaling strategies: Fey receptor-mediated phagocytosis as a model system. Semin. Immunol. (2001) 13(6):339–345.
   PubMed Web of Science ®Google Scholar
• TAKAI T, LI M, SYLVESTRE D, CLYNES R, RAVETCH JV: FcRy chain deletion results in pleiotrophic effector cell defects. Cell (1994) 76(3):519–529. First report of in vivo function of FcRy
   Google Scholar
• FITZER-ATTAS CJ, CROWLEY MT, FINN AJ, MENG F, DEFRANCO AL, LOWELL CA: Fc receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr and Lyn. J. Exp. Med. (2000) 191(4):669–682.
   PubMed Web of Science ®Google Scholar
• CROWLEY MT, COSTELLO PS, FITZER-ATTAS CJ et al: A critical role for Syk in signal transduction and phagocytosis mediated by Fc receptors on macrophages. J. Exp. Med. (1997) 186(7):1027–1039.
   PubMed Web of Science ®Google Scholar
• KIEFER F, BRUMELL J, AL-ALAWIl N et al: The Syk protein tyrosine kinase is essential for Fc receptor signaling in macrophages and neutrophils. Mot Cell Biol. (1998) 18(7):4209–4220.
   Web of Science ®Google Scholar
• KARIMI K, GEMMILL TR, LENNARTZ MR: Protein kinase C and a calcium-independent phospholipase are required for IgG-mediated phagocytosis by Mono-Mac-6 cells. J. Leukoc. Biol. (1999) 65(6):854–862.
   PubMed Web of Science ®Google Scholar
• BRETON A, DESCOTEAUX A: Protein kinase C-a participates in FcyR-mediated phagocytosis in macrophages. Biochem. Biophys. Res. Commun. (2000) 276(2):472–476.
   PubMed Web of Science ®Google Scholar
• HAZAN-HALEVY I, SWGER R, LEVY R: The requirement of both extracellular regulated kinase and p38 mitogen-activated protein kinase for stimulation of cytosolic phospholipase A(2) activity by either FcyRIIA or FcyRIIIB in human neutrophils. A possible role for Pyk2 but not for the Grb2-Sos-Shc complex. J. Chem. (2000) 275(17):12416–12423.
   Google Scholar
• BOTELHO RJ, TERUEL M, DIERCKMAN R et al.: Localized biphasic changes in phosphatidylinosito1-4,5-bisphosphate at sites of phagocytosis. ./. Cell. Biol. (2000) 151(7):1353–1368.
   PubMed Web of Science ®Google Scholar
• KUSNER DJ, HALL CE JACKSON S: Fey receptor-mediated activation of phospholipase D regulates macrophage phagocytosis of IgG-opsonized particles. Immunol. (1999) 162(4):2266–2274.
   Web of Science ®Google Scholar
• LEVERRIER Y, OKKENHAUG K, SAWYER C, BILANCIO A, VANHAESEBROECK B, RIDLEY AJ: Class I phosphoinositide 3-kinase p11013 is required for apoptotic cell and Fey receptor-mediated phagocytosis by macrophages. J. Biol. Chem. (2003) 278(40)38437–38442.
   Google Scholar
• SONG X, TANAKA S, COX D, LEE SC: Fcy receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction. J. Leukoc. Biol. (2004) 75(6):1147–1155.
   PubMed Web of Science ®Google Scholar
• EDBERG JC, UN CT, LAUD, UNKELESS JC, KIMBERLY R: The Ca2' dependence of human Fey receptor-initiated phagocytosis. J. Biol. Chem. (1995) 270(38):22301–22307.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, TAKAHASHI K, NAGASAWA S: The role of tyrosine phosphorylation and Ca2' accumulation in Fey-receptor-mediated phagocytosis of human neutrophils. j Biochem. (1995) 117(6):1156–1161.
   PubMed Web of Science ®Google Scholar
• CHIMINI G, CHAVRIER P: Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. Nat. Cell. Biol. (2000) 2(10):E191–E196.
   Web of Science ®Google Scholar
• DIAKONOVA M, BOKOCH G, SWANSON JA: Dynamics of cytoskeletal proteins during Fey receptor-mediated phagocytosis in macrophages. Mo/. Biol Cell. (2002) 13(2):402–411.
   PubMed Web of Science ®Google Scholar
• MARSHALL JG, BOOTH JW, STAMBOLIC V et al.: Restricted accumulation of phosphatidylinositol 3-kinase products in a plasmalemmal subdomain during Fey receptor-mediated phagocytosis. ./. Cell. Biol. (2001) 153(7):1369–1380.
   PubMed Web of Science ®Google Scholar
• VIEIRA OV, BOTELHO RJ, RAMEH L et al.: Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J. Cell. Biol. (2001) 155(1):19–25.
   PubMed Web of Science ®Google Scholar
• GU H, BOTELHO RJ, YU M, GRINSTEIN S, NEEL BG: Critical role for scaffolding adapter Gab2 in FcyR-mediated phagocytosis. ./. Cell. Biol. (2003) 161(6):1151–1161.
   PubMed Web of Science ®Google Scholar
• VAN LENT P, NABBE KC, BOROSS P et al.: The inhibitory receptor FcyRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcyRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol. (2003) 163(5):1839–1848.
   PubMed Web of Science ®Google Scholar
• HARA I, TAKECHI Y, HOUGHTON AN: Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. ./. Exp. Med. (1995) 182(5):1609–1614.
   PubMed Web of Science ®Google Scholar
• CLYNES R, TAKEUCHI Y, MOROI Y, HOUGHTON A, RAVETCH JV: Fc receptors are required in passive and active immunity to melanoma. Proc. Nati Acad. Sci. USA (1998) 95(2):652–656.
   PubMed Web of Science ®Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6(4): 443–446.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, YAMAGUCHI N, AKIBA H et al.: Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy J. Exp. Med. (2004) 199(4):437–448.
   PubMed Web of Science ®Google Scholar
• AKIYAMA K, EBIHARA S, YAD A et al.: Targeting apoptotic tumor cells to FcyR provides efficient and versatile vaccination against tumors by dendritic cells. Immunol. (2003) 170(4):1641–1648.
   Web of Science ®Google Scholar
• YADA A, EBIHARA S, MATSUMURA K et al.: Accelerated antigen presentation and elicitation of humoral response in vivo by FcyRIIB- and FcyRI/III-mediated immune complex uptake. Cell. Immunol. (2003) 225(1):21–32.
   PubMed Web of Science ®Google Scholar
• •[77,78] demonstrated the positive contribution of FcyRIIB in antigen presentation by DCs.
   Google Scholar
• REGNAULT A, LANKAR D, LACABANNE V et al.: Fey receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. ./. Exp. Med. (1999) 189(2):371–380.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ A, REGNAULT A, KLEIJMEER M, RICCIARDI-CASTAGNOLI P, AMIGORENA S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell. Biol. (1999) 1(6):362–368.
   PubMed Web of Science ®Google Scholar
• DHODAPKAR KM, KRASOVSKY J, WILLIAMSON B, DHODAPKAR MV: Antitumor monoclonal antibodies enhance cross-presentation of cCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. (2002) 195(1):125–133.
   PubMed Web of Science ®Google Scholar
• KALERGIS AM, RAVETCH JV: Inducing tumor immunity through the selective engagement of activating Fey receptors on dendritic cells. .1 Exp. Med. (2002) 195(12):1653–1659.
   Google Scholar
• ZUM BUSCHENFELDE CM, HERMANN C, SCHMIDT B, PESCHEL C, BERNHARD H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. (2002) 62(8):2244–2247.
   PubMed Web of Science ®Google Scholar
• MOSTOV KE, FRIEDLANDER M, BLOBEL G: The receptor for transepithelial transport of IgA and IgM contains multiple immunoglobulin-like domains. Nature (1984) 308(5954):37–43.
   PubMed Web of Science ®Google Scholar
• MOURA IC, CENTELLES MN, ARCOS-FAJARDO M et al.: Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J. Exp. Med. (2001) 194(4):417–425.
   PubMed Web of Science ®Google Scholar
• RAMALINGAM TS, DETMER SA, MARTIN WL, BJORKMAN PJ: IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J. (2002) 21(4):590–601.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, CLAYPOOL SM, WAGNER JS et al.: Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 20(6):769–783.
   PubMed Web of Science ®Google Scholar
• DONNADIEU E, JOUVIN MH, KINET JP: A second amplifier function for the allergy-associated FccRI-13 subunit. Immunity (2000) 12(5):515–523.
   PubMed Web of Science ®Google Scholar
• DONNADIEU E, JOUVIN MH, RANA S et al.: Competing functions encoded in the allergy-associated FccRII3 gene. Immunity (2003) 18(5):665–674.
   PubMed Web of Science ®Google Scholar
• TAKAI T, ONO M: Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol. Rev. (2001) 181:215–222.
   PubMed Web of Science ®Google Scholar
• DOMBROWICZ D, FLAMAND V, BRIGMAN KK, KOLLER BH, KINET JP: Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor a chain gene. Cell (1993) 75(5):969–976.
   PubMed Web of Science ®Google Scholar
• DOMBROWICZ D, FLAMAND V, MIYAJIMA I, RAVETCH JV, GALLI SJ, KINET JP: Absence of FccRIa chain results in upregulation of FcyRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between FccRI and FcyRIII for limiting amounts of FcRI3 and y chains. Clin. Invest. (1997) 99(5):915–925.
   Google Scholar
• UJIKE A, ISHIKAWA Y, ONO M et al.: Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J. Exp. Med. (1999) 189(10):1573–1579.
   PubMed Web of Science ®Google Scholar
• IOAN-FACSINAY A, DE KIMPE SJ, HELLWIG SM et al: FcyRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 16(3):391–402.
   PubMed Web of Science ®Google Scholar
• STIEF A, TEXIDO G, SANSIG G, EIBEL H, LE GROS G, VAN DER PUTTEN H: Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. ./. Immunol (1994) 152(7):3378–3390.
   PubMed Web of Science ®Google Scholar
• YU P, KOSCO-VILBOIS M, RICHARDS M, KOHLER G, LAMERS MC: Negative feedback regulation of IgE synthesis by murine CD23. Nature (1994) 369(6483):753–756.
   PubMed Web of Science ®Google Scholar
• TEXIDO G, EIBEL H, LE GROS G, VAN DER PUTTEN H: Transgene CD23 expression on lymphoid cells modulates IgE and IgG1 responses. J. Immunol (1994) 153(7):3028–3042.
   PubMed Web of Science ®Google Scholar
• BENDELAC A, BONNEVILLE M, KEARNEY JF: Autoreactivity by design: innate B and T lymphocytes. Nat. Rev Immunol (2001) 1(3):177–186.
   PubMed Web of Science ®Google Scholar
• KLEINAU S, MARTINSSON P, HEYMAN B: Induction and suppression of collagen-induced arthritis is dependent on distinct Fc receptors. J. Exp. Med. (2000) 191(9):1611–1616.
   PubMed Web of Science ®Google Scholar
• NAKAMURA A, NUKIWA T, TAKAI T: Deregulation of peripheral B-cell development in enhanced severity of collagen-induced arthritis in FcyRIIB-deficient mice. Autoimmun. (2003) 20(3):227–236.
   Web of Science ®Google Scholar
• PARK SY, UEDA S, OHNO H et al: Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. Clin. Invest. (1998) 102(6):1229–1238.
   Google Scholar
• WAKAYAMA H, HASEGAWA Y, KAWABE T et al: Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRy-deficient mice. Eur. j Immunol (2000) 30(4):1182–1190.
   PubMed Web of Science ®Google Scholar
• CLYNES R, DUMITRU C, RAVETCH JV: Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science (1998) 279(5353):1052–1054.
   PubMed Web of Science ®Google Scholar
• JI H, OHMURA K, MALHMOOD U et al.: Arthritis critically dependent on innate immune system players. Immunio, (2002) 16(2):157–168.
   PubMed Web of Science ®Google Scholar
• KAGARI T, TANAKA D, DOI H, SHIMOZATO T: Essential role of Fcy receptors in anti-type II collagen antibody-induced arthritis. Immunol (2003) 170(8):4318–4324.
   Web of Science ®Google Scholar
• MACCIONI M, ZEDER-LUTZ G, HUANG H et al: Arthritogenic monoclonal antibodies from K/BxN mice. J. Exp. Med. (2002) 195(8):1071–1077.
   PubMed Web of Science ®Google Scholar
• DIAZ DE STAHL T, ANDREN M, MARTINSSON P, VERBEEK JS, KLEINAU S: Expression of FcyRIII is required for development of collagen-induced arthritis. Eur. Immunol (2002) 32(10):2915–2922.
   PubMed Web of Science ®Google Scholar
• MEYER D, SCHILLER C, WESTEMANN J et al.: FcyRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood (1998) 92(11):3997–4002.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, SHIRATO I, OKUMURA K et al.: Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. (1998) 54(4):1166–1174.
   PubMed Web of Science ®Google Scholar
• CLYNES R, MAIZES JS, GUINAMARD R, ONO M, TAKAI T, RAVETCH JV: Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. (1999) 189(1):179–185.
   PubMed Web of Science ®Google Scholar
• NAKAMURA A, YUASA T, UJIKE A et al.: Fey receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with Type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. (2000) 191(5):899–906.
   PubMed Web of Science ®Google Scholar
• COURTENAY JS, DALLMAN MJ, DAYAN AD, MARTIN A, MOSEDALE B: Immunization against heterologous Type II collagen induces arthritis in mice. Nature (1980) 283(5748):666–668.
   PubMed Web of Science ®Google Scholar
• TRENTHAM DE, TOWNES AS, KANG AH: Autoimmunity to Type II collagen an experimental model of arthritis. J. Exp. Med. (1977) 146(3):857–868.
   PubMed Web of Science ®Google Scholar
• WOOLEY PH, LUTHRA HS, STIART JM, DAVID CS: Type II collagen induced arthritis in mice. I. Major histocompatibility complex (I-region) linkage and antibody correlates. J. Exp. Med. (1981) 154(3):688–700.
   Google Scholar
• YUASA T, KUBO S, YOSHINO T et al.: Deletion of Fey receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. I Exp. Med. (1999) 189(1):187–194.
   PubMed Web of Science ®Google Scholar
• BOLLAND S, RAVETCH JV: Spontaneous autoimmune disease in FcyRIIB-deficient mice results from strain-specific epistasis. Immunity (2000) 13(2):277–285.
   PubMed Web of Science ®Google Scholar
• WAKELAND EK, LIU K, GRAHAM RR, BEHRENS TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity (2001) 15(3):397–408.
   PubMed Web of Science ®Google Scholar
• KELLY VE, ROTHS JB: Interaction of mutant lpr gene with background strain influences renal disease. Clin. Immunol Immunopathol (1985) 37(2):220–229.
   PubMedGoogle Scholar
• ANDREWS BS, EISENBERG RA, THEOFILOPOULOS AN et al: Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. (1978) 148(5):1198–1215.
   Google Scholar
• YAJIMA K, NAKAMURA A, SUGAHARA A, TAKAI T: FcyRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur. Immunol (2003) 33(4):1020–1029.
   PubMed Web of Science ®Google Scholar
• SINCLAIR NR: Fc-signalling in the modulation of immune responses by passive antibody. Scand. I Immunol (2001) 53(4):322–330.
   PubMed Web of Science ®Google Scholar
• TAKAI T, NAKAMURA A, AKIYAMA K: Fc receptors as potential targets for the treatment of allergy, autoimmune disease and cancer. Curr. Drug. Targets. Immune. Endocr. Metabol Disord. (2003) 3(3):187–197.
   PubMedGoogle Scholar
• KINET JP: Atopic allergy and other hypersensitivities. Curr. Opin. Immunol (1999) 11(6):603–605.
   PubMed Web of Science ®Google Scholar
• WEINBERGER M: Innovative therapies for asthma: anti-IgE - the future? Paediam Respir. Rev (2004) 5(Suppl. A):5115–5118.
   Google Scholar
• BUSSE W NEAVILLE W: Anti-immunoglobulin E for the treatment of allergic disease. Curr. Opin. Allergy Clin. Immunol (2001) 1(1):105–108.
   PubMed Web of Science ®Google Scholar
• ZAGURY D, GALLO RC: Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov. Today (2004) 9(2):72–81.
   PubMed Web of Science ®Google Scholar
• MIESCHER SM, VOGEL M: Molecular aspects of allergy. Mol Aspects Med. (2002) 23(6):413–462.
   PubMed Web of Science ®Google Scholar
• GOODNOW CC: Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet (2001) 357(9274):2115–2121.
   PubMed Web of Science ®Google Scholar
• SCOFIELD RH: Autoantibodies as predictors of disease. Lancet (2004) 363(9420):1544–1546.
   PubMed Web of Science ®Google Scholar
• OLSEN1NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl. I Med. (2004) 350(21):2167–2179.
   PubMed Web of Science ®Google Scholar
• ••General overview of the treatment of theanticytokine antibodies in RA patients.
   Google Scholar
• FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev Immunol (1996) 14:397–440.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Ann. Rev Immunol (2001) 19:163–196.
   Google Scholar
• BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-a antibody with the interleukin-1 receptor antagonist. Eur. Cytokine. Netw. (1995) 6(4):225–230.
   Google Scholar
• CHOY EH, ISENBERG DA, GARROOD T et al: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. (2002) 46(12):3143–3150.
   PubMed Web of Science ®Google Scholar
• NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50(6):1761–1769.
   PubMed Web of Science ®Google Scholar
• DE MIGUEL S, JOVER JA, VADILLO C, JUDEZ E, LOZA E, FERNANDEZ-GUTIERREZ B: B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin. Exp. Rheumatol (2003) 21 (6):726–732.
   Google Scholar
• KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. Clin. Invest. (1996) 98(3):826–837.
   Google Scholar
• DESAI-MEHTA A, LU L, RAMSEY-GOLDMANOL R, DATTA SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. Clin. Invest. (1996) 97(9):2063–2073.
   Google Scholar
• KATO K, SANTANA-SAHAGON E, RASSENTI L Z et al: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. ./. Clin. Invest. (1999) 104(7):947–955.
   Google Scholar
• GRAMMER AC, SLOTA R, FISHER R et al: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. Clin. Invest. (2003) 112(10):1506–1520.
   Google Scholar
• KALUNIAN KC, DAVIS JC Jr, MERRILL JT, TOTORITIS MC, WOFSY D: IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis. Rheum. (2002) 46(12):3251–3258.
   Google Scholar
• KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. (2000) 6(2):114.
   Web of Science ®Google Scholar
• GORMAN C, LEANDRO M, ISENBERG D: B cell depletion in autoimmune disease. Arthritis. Res. Ther. (2003) 5\(Suppl. 4):517–521.
   Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673–2677.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl. J. Med. (2004) 350(25):2572–2581.
   PubMed Web of Science ®Google Scholar
• GOPAL AK, PRESS OW: Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. (1999) 134(5):445–450.
   PubMed Web of Science ®Google Scholar
• UCHIDA J, HAMAGUCHI Y, OLIVER JA et al: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. I Exp. Med. (2004) 199(12):1659–6169.
   PubMed Web of Science ®Google Scholar
• •Describes the possible mechanism of anti-CD20 antibody therapy.
   Google Scholar
• ANOLIK JH, CAMPBELL D, FELGAR RE et al.: The relationship of FcyRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48(2):455–459.
   PubMed Web of Science ®Google Scholar
• RASTETTER W, MOLINA A, WHITE CA: Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Ann. Rev Med. (2004) 55:477–503.
   PubMed Web of Science ®Google Scholar
• GLENNIE MJ, JOHNSON PW: Clinical trials of antibody therapy. Immunol. Today (2000) 21(8):403–410.
   PubMedGoogle Scholar
• GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 25(3):158–164.
   Google Scholar
• HARRIS M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol (2004) 5(5):292–302.
   PubMed Web of Science ®Google Scholar
• ANDERSON K, BATES M, SLAUGHENHOUPT B, PINKUS GS, SCHLOSSMAN SF, NADLER LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 63(6):1424–1433.
   PubMed Web of Science ®Google Scholar
• HEROLD M, DOLKEN G, FIEDLER F et al.: Randomized Phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann. Hematol (2003) 82(2):77–79.
   PubMed Web of Science ®Google Scholar
• •Describes the therapeutic effect of rituximab in lymphoma patients.
   Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcyRIIIa gene. Blood (2002) 99(3):754–758.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99(10):3554–3561.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, ZHANG M, GOLDMAN CK, RAVETCH JV, WALDMANN TA: Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer. Res. (2003) 63(19):6453–6457.
   PubMed Web of Science ®Google Scholar
• SLAMON1DJ, GOD OLPHIN W, JONES LA et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707–712.
   PubMed Web of Science ®Google Scholar
• MOSESSON Y, YARDEN Y: Oncogenic growth factor receptors: implications for signal transduction therapy. &min. Cancer Biol. (2004) 14(4):262–270.
   PubMed Web of Science ®Google Scholar
• SLIWKOWSKI MX, LOFGREN JA, LEWIS GD, HOTALING TE, FENDLY BM, FOX JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). &min. Oncol (1999) 4\(Suppl. 12):60–70.
   Google Scholar
• KONO K, SATO E, NAGANUMA H et al: Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin. Cancer. Res. (2004) 10(7):2538–2544.
   PubMed Web of Science ®Google Scholar
• VAN SPRIEL AB, VAN OJIK HH, VAN DE WINKEL JG: Immunotherapeutic perspective for bispecific antibodies. Immunol Today (2000) 21(8):391–397.
   PubMedGoogle Scholar
• PEIPP M, VALERIUS T: Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. (2002) 30(4):507–511.
   PubMed Web of Science ®Google Scholar
• UMASIA P, JEAN-MAIRET J, MOUDRY R, AMSTUTZ H, BAILEY JE: Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. (1999) 17(2):176–180.
   PubMed Web of Science ®Google Scholar
• IERINO FL, POWELL MS, MCKENIECK IF, HOGARTH PM: Recombinant soluble human Fcy RII: production, characterization, and inhibition of the Arthus reaction. ./. Exp. Med. (1993) 178(5):1617–1628.
   PubMed Web of Science ®Google Scholar
• JOHANSSON AC, SUNDLER M, KJELLEN P et al.: Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcyRIIB and is not associated with loci controlling diabetes. Eur. brimunol. (2001) 31(6):1847–1856.
   PubMed Web of Science ®Google Scholar
• TRACZYK C, OKAYAMA Y, METCALFE DD, GLIFILLAN AM: Fcy receptors on mast cells: activating and inhibitory regulation of mediator release. Int. Arch. Allergy Immunol (2004) 133(3):305–315.
   PubMed Web of Science ®Google Scholar
• KYOGOKU C, DIJSTELBLOEM HM, TSUCHIYA N et al: Fcy receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus. Arthritis Rheum. (2002) 46(5):1242–1254.
   PubMed Web of Science ®Google Scholar
• MAGNUSSON V, ZUNEC R, ODEBERG J et al.: Polymorphisms of the Fcy receptor Type IIB gene are not associated with systemic lupus erythematosus in the Swedish population. Arthritis. Rheum. (2004) 50 (4) :1348–1350.
   PubMed Web of Science ®Google Scholar
• SU K, WU J, EDBERG JC et al: A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcyRIIB alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. ./. Immunol (2004) 172(11):7186–7191.
   Google Scholar
• SU K, LI X, EDBERG JC et al.: A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcyRIIB alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yangl transcription factors and correlated receptor expression and function. Immunol (2004) 172(10:7192–7199.
   Google Scholar
• VAB DEN HERIK-OUDIJK IE, WESTERDAAL NA, HENRIQUEZ NV, CAPEL PJ, VAN DE WINKEL JG: Functional analysis of human Fcy RII (CD32) isoforms expressed in Blymphocytes. J. Immunol (1994)152(2):574–585.
   PubMed Web of Science ®Google Scholar
• CINES DB, BLANCHETTE1 VS: Immune thrombocytopenic purpura. N Engl. J. Med. (2002) 346(13):995–1008.
   PubMed Web of Science ®Google Scholar
• YUKI N: Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. (2001) 1(1):29–37.
   PubMedGoogle Scholar
• DURELLI L, ISOARDO G: High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol Li. (2002) 23\(Suppl. 1):539–548.
   Google Scholar
• LATOV N, CHAUDHRY V, KOSKI CL et al.: Use of intravenous gamma globulins in neuroimmunologic diseases. I Allergy OM Immunol (2001) 108(4 Suppl.):S126–S132.
   Google Scholar
• WILES CM, BROWN P, CHAPEL H et al: Intravenous immunoglobulin in neurological disease: a specialist review. I Neurol Neurosurg. Psychiatry (2002) 72(4):440–448.
   PubMed Web of Science ®Google Scholar
• BURNS JC: Kawasaki disease. Adv. Pediatr. (2001) 48:157–177.
   PubMedGoogle Scholar
• SEWELL WA, JOLLES S: Immunomodulatory action of intravenous immunoglobulin. Immunology (2002) 107(4):387–393.
   PubMed Web of Science ®Google Scholar
• SIMON HU, SPATH PJ: IVIg - mechanisms of action. Allergy (2003) 58(7):543–552.
   PubMed Web of Science ®Google Scholar
• BAYRY J, MISRA N, LATRY V et al: Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus. Clin. Biol. (2003) 10(3):165–169.
   Google Scholar
• SAMUELSSON A, TOWERS TL, RAVETCH JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 291(5503):484–486.
   PubMed Web of Science ®Google Scholar
• ••Describes the FcyRIIB implicationIn IVIg treatment.
   Google Scholar
• BRUHNS P, SAMUELSSON A, POLLARD JW, RAVETCH JV: Colony-stimulating factor- 1 -dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 18(4):573–581.
   PubMed Web of Science ®Google Scholar
• CROW AR, SONG S, FREEDMAN J et al: IVIg-mediated amelioration of murine ITP via FcyRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood (2003) 102(2):558–560.
   PubMed Web of Science ®Google Scholar
• AKILESH S, PETKOVA S, SPROULE TJ, SHAFFER DJ, CHRISTIANSON GJ, ROOPENIAN D: The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. ./. Clin. Invest. (2004) 113(9):1328–1333.
   Google Scholar
• ••Demonstrates that FcRn, as well asFcyRIIB, contributes to the therapeutic effect of IVIg treatment.
   Google Scholar
• MCDONNEL JM, BEAVIL AJ, MACKAY GA et al: Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat. Struct. Biol. (1996) 5(3):419–426.
   Google Scholar
• MARINO M, RUVO M, DE FALCO S, FASSINA G: Prevention of systemic lupus erythematosus in MRU/pr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol. (2000) 18(7):735–739.
   PubMed Web of Science ®Google Scholar
• URAY K, MEDGYESI D, HILBERT A, SARMAY G, GERGELY J, HUDECZ F: Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region. Mol. Recognit. (2004) 17(2):95–105.
   PubMed Web of Science ®Google Scholar
• MEDGYSEI D, URAY K, SALLAI K et al: Functional mapping of the FcyRII binding site on human IgG1 by synthetic peptides. Eur. knnunol. (2004) 34(4):1127–1135.
   Google Scholar